To download a PDF of the programme click here.
For further information on this event please contact us.
Day One
Tuesday 28th March 2023
09.30 Onwards
Registration
10.00-10.15
Welcome & Opening Remarks
Moderator: Mark R. Prausnitz
(Georgia Institute of Technology, Atlanta, Georgia, USA)
SESSION 1:
OPENING PLENARY SESSION
Moderator: Mark R. Prausnitz
(Georgia Institute of Technology, Atlanta, Georgia, USA)
10.15-11.00
Opening Keynote:
‘Skin delivery: Lotions, potions and more radical notions’
James Birchall
(Cardiff University, Cardiff, Wales, UK)
11.00-11.30
‘Targeting Skin Dendritic cells’
Esther C. de Jong
(Dept. Experimental Immunology, Amsterdam UMC, Amsterdam, The Netherlands)
11.30-12.15
Keynote Presentation:
‘The future of ID vaccination in the context of pandemic response: Data from intradermal flu, intradermal COVID and other vaccines’
Yotam Levin
(NanoPass, Israel)
12.15-13.30
Lunch Break
SESSION 2:
GLOBAL
Moderator: James Birchall
(Cardiff University, Cardiff, Wales, UK)
13.30-13.45
‘Pandemic Preparedness: The Future Role of the Pandemic Sciences Institute in Oxford’
Sarah Gilbert
(The Pandemic Sciences Institute, Oxford, UK)
13.45-14.15
‘PATH Center of Excellence for Microarray Patch Technology: Designing target product profiles for microarray patch applications of global public health importance’
Collrane Frivold, Jessica Mistilis, Jennifer Foster, Manjari Quintanar-Solares and Courtney Jarrahian
(PATH, Seattle, Washington, United States)
14.15-14.45
‘The experience of intradermal administration of fractional dose inactivated poliovirus by the Global Polio Eradication Initiative (GPEI)’
Grace Macklin
(World Health Organization, Geneva, Switzerland)
14.45-15.15
Tea Break
SESSION 3:
MICROARRAY TECHNOLOGY & RESPONSES
Moderator: Anne Moore
(University College Cork, Cork, Ireland)
15.15-15.45
‘Delivery of a COVID-19 vaccine to the skin using a High Density-Microarray Patch protects mice from SARS-CoV-2 infection’
Christopher L.D. McMillan1,2, Jovin J.Y. Choo1, Paul R. Young1,2 and David A. Muller1,2
(1 The University of Queensland, St Lucia, Queensland, Australia; 2 Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland, Australia)
15.45-16.15
‘Microneedle technologies and liposomal delivery systems for (cancer) vaccination’
Koen van der Maaden
(Leiden University Medical Center (LUMC), Leiden, The Netherlands)
16.15-16.45
‘Using spatial transcriptomics to unravel the mechanism of high-density microarray patch vaccination’
Christopher L.D. McMillan1,2, Jovin J.Y. Choo1, Helle Bielefeldt-Ohmann1,2,3, Paul R. Young1,2,4, and David A. Muller1,2
(1 University of Queensland, St Lucia, Queensland , Australia; 2 Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland, Australia; 3 University of Queensland Gatton Campus, Gatton, Queensland, Australia)
16.45
Close of Day 1
Day Two
Wednesday 29th March 2023
SESSION 4:
MICRONEEDLE PATCHES
Moderator: To be confirmed
09.00-09.45
‘Measles and rubella vaccination by microneedle patch’
Mark R. Prausnitz, Jeong Woo Lee and Yasmione Gomaa
(Georgia Institute of Technology, Atlanta, Georgia, USA)
09.45-10.30
‘Defining the range of adjuvants suitable for use with dissolvable microneedle patches’
Anne Moore
(University College Cork, Cork, Ireland)
10.30-11.00
‘A thermostable microneedle patch for tetanus toxoid vaccination’
Andrey V. Romanyuk1, Ioanna Skountzou2 and Mark R. Prausnitz1
(1 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; 2 Department of Microbiology & Immunology, Emory University, Atlanta, Georgia, USA)
11.00-11.30
Coffee Break
SESSION 5:
MICROARRAY PATCHES
Moderator: To be confirmed
11.30-12.00
‘Skin vaccination with Ebola virus glycoprotein using a polyphosphazene-based microneedle patch protects mice against lethal challenge’
Andrey Romanyuk1, Ruixue Wang2, Alexander Marin2, Benjamin M. Janus2, Eric I. Felner1,3, Dengning Xia1,4, Yenny Goez-Gazi5, Kendra J. Alfson5, Abdul S. Yunus2, Eric A. Toth2, Gilad Ofek2,6, Ricardo Carrion, Jr.5, Thomas R. Fuerst2, Alexander K. Andrianov2 and Mark R. Prausnitz1
( 1 Georgia Institute of Technology, Atlanta, Georgia, USA; 2 University of Maryland, Rockville, Maryland, USA; 3 Emory University Atlanta, Georgia, USA; 4 Sun Yat-sen University, Shenzhen 518107, China; 5 Texas Biomedical Research Institute, San Antonio, Texas, USA)
12.00-12.25
‘Assessment of the acceptability and programmatic suitability of an HPV vaccine microarray patch in Ethiopia’
Manjari Quintanar-Solares1, Temesgen Lemma2, Amare Bayeh2, Collrane Frivold1 and Courtney Jarrahian1
( 1 PATH, Seattle, Washington, USA; 2 PATH Ethiopia, Addis Ababa, Ethiopia)
12.25-12.45
‘Evalutation of a novel insect-specific flavivirus chimera vaccine candidate delivered to the skin by high-density microarray patches in a dengue challenge mouse model’
Jovin J.Y. Choo, Laura Vet, J Hobson-Peters, Germain J.P. Fernando, R.A. Hall, P.R. Young and D.A. Muller
(Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Queensland, Australia)
12.45-14.00
Lunch Break
SESSION 6:
DELIVERY
Moderator: To be confirmed
14.00-14.30
‘Title to be confirmed’
Koen Van der Maaden
(LUMC, Leiden, The Netherlands)
14.30-15.00
‘Vaxess Technologies: A clinical stage skin-patch for vaccine delivery’
Livio Valenti
(Vaxess Technologies, Cambridge, Massachusetts, USA)
15.00-15.30
‘Pre-clinical evaluation of VAX-ID®; A device for standardized, accurate, and user-independent intradermal vaccination’
Momen Naim Mousa Rbeihat
(Idevax BV, Wijnegem, Belgium)
15.30-16.00
Tea Break
SESSION 7:
VACCINES & VACCINATION
Moderator: Esther de Jong
(University of Amsterdam, Amsterdam, The Netherlands)
16.00-16.30
‘NanoVAX®, a mucosal adjuvant enhances uptake and adjuvants epicutaneously delivered vaccines and Shifting the immune response from Th2 to Th1 and mucosal immunity, Th17’
Ali I. Fattom
(Bluewillow Biologics, Ann Arbor, Michigan, USA)
16.30-17.00
‘Neonatal and adult innate immune responses to microneedle-mediated vaccination through the skin’
Anne Moore
(University College Cork, Cork, Ireland)
17.00
Close of Day 2
Day Three
Thursday 30th March 2023
SESSION 8:
DEVICES
Moderator: Anne Moore
(University College Cork, Cork, Ireland)
09.00-09.30
‘Financing, business development, founding and building drug delivery: Microneedle patch technology devices for skin delivery’
Steve Damon
(Micron Biomedical Inc., Atlanta, Georgia, USA)
09.30-10.00
‘Commercial intradermal needle-free injection system: Advancing current and future injectables’
Erin Spiegel
(Pharmajet Inc., Golden, Colorado, USA)
10.00-10.30
‘Evaluating skin biological responses using a novel tension-based ex vivo human skin model’
Michael Conneely
(Ten Bio Ltd, Dundee, Scotland, UK)
10.30-11.00
Coffee Break
SESSION 9:
PANEL DISCUSSION
11.00-12.00
‘Transdermal Vaccination: Forward Directions’
Discussion Leader: Mark R. Prausnitz
(Georgia Institute of Technology, Atlanta, Georgia, USA)
12.00-12.10
Including Closing Remarks
12.10
Lunch & Departure
LATEBREAKER POSTERS
‘Inactivated influenza virus-loaded Egg microneedle for accurate
and efficient transdermal vaccination’
Geonwoo Kang1, Jeehye Nam2, Hye Su Min2 and Hyungil Jung1,2
( 1 Juvic Inc., Guro-gu, Seoul, Republic of Korea; 2 Yonsei University,
Seodaemun-gu, Seoul, Republic of Korea)
‘Pre-clinical evaluation of VAX-ID®: A device for standardized, accurate, and user-independent intradermal vaccination’
Momen Naim Mousa Rbeihat
(Idevax BV, Wijnegem, Belgium)
‘Latch applicator for easy and efficient skin vaccination via dissolving microneedles’
Hye Su Min
(Yonsei University, Yonsei, Republic of Korea)
This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.